PHARMACEUTICAL IP

  • Offering
    • Evolve AI
      • Albert (Validity)
        • Validity analysis
        • Albert Construe (Claim construction)
      • Popper (Prosecution)
      • Franklin (Publication review)
      • AI for Sequences
    • Fractional IP counsel
    • Services
      • AI guidance
      • Competitive intelligence
      • Deals
      • Due diligence
      • Freedom to operate
      • IP strategy and communication
      • Oppositions and appeals
      • Patent drafting
      • Patent prosecution
      • Trade secrets
    • Technologies
      • Pharmaceuticals
      • Biologics
      • Cell & gene therapy
      • AI drug discovery
    • Our clients
      • Biotech
      • CROs and CMOs
      • Established pharma
      • International IP counsel
      • Investors
      • Start-ups
      • Universities
  • Fractional IP counsel
    • Fractional IP counsel
    • What is fractional IP counsel?
    • Our clients
      • Biotech
      • CROs and CMOs
      • Established pharma
      • International IP counsel
      • Investors
      • Start-ups
      • Universities
  • Evolve AI
    • Albert (Validity)
      • Validity analysis
      • Albert Construe (Claim construction)
    • Popper (Prosecution)
    • Franklin (Publication review)
    • AI for Sequences
  • Technologies
    • Pharmaceuticals
      • Dosing regimens
      • Formulations
      • Life cycle management
      • New indications
      • Platform technologies
    • Biologics
      • Antibodies
      • Antibody-drug conjugates (ADCs)
      • T cell engagers (TCEs)
    • Cell & gene therapy
      • CAR-T cell therapies
      • Gene therapies
      • In vivo CAR-T
      • Lipid nanoparticles (LNPs)
      • Macrophages (CAR-M)
      • mRNA therapeutics
      • Regenerative cell therapies
    • AI drug discovery
  • Insights
    • Articles
    • Pharma IP Toolkit
    • Evolve Guides
    • Events & Webinars
    • Subscribe
  • About us
    • Our team
    • Recognition
    • Join us
    • Contact us
  • Offering
    • Evolve AI
      • Albert (Validity)
        • Validity analysis
        • Albert Construe (Claim construction)
      • Popper (Prosecution)
      • Franklin (Publication review)
      • AI for Sequences
    • Fractional IP counsel
    • Services
      • AI guidance
      • Competitive intelligence
      • Deals
      • Due diligence
      • Freedom to operate
      • IP strategy and communication
      • Oppositions and appeals
      • Patent drafting
      • Patent prosecution
      • Trade secrets
    • Technologies
      • Pharmaceuticals
      • Biologics
      • Cell & gene therapy
      • AI drug discovery
    • Our clients
      • Biotech
      • CROs and CMOs
      • Established pharma
      • International IP counsel
      • Investors
      • Start-ups
      • Universities
  • Fractional IP counsel
    • Fractional IP counsel
    • What is fractional IP counsel?
    • Our clients
      • Biotech
      • CROs and CMOs
      • Established pharma
      • International IP counsel
      • Investors
      • Start-ups
      • Universities
  • Evolve AI
    • Albert (Validity)
      • Validity analysis
      • Albert Construe (Claim construction)
    • Popper (Prosecution)
    • Franklin (Publication review)
    • AI for Sequences
  • Technologies
    • Pharmaceuticals
      • Dosing regimens
      • Formulations
      • Life cycle management
      • New indications
      • Platform technologies
    • Biologics
      • Antibodies
      • Antibody-drug conjugates (ADCs)
      • T cell engagers (TCEs)
    • Cell & gene therapy
      • CAR-T cell therapies
      • Gene therapies
      • In vivo CAR-T
      • Lipid nanoparticles (LNPs)
      • Macrophages (CAR-M)
      • mRNA therapeutics
      • Regenerative cell therapies
    • AI drug discovery
  • Insights
    • Articles
    • Pharma IP Toolkit
    • Evolve Guides
    • Events & Webinars
    • Subscribe
  • About us
    • Our team
    • Recognition
    • Join us
    • Contact us
  • Offering
  • What is fractional IP counsel?
  • Evolve AI
  • Technologies
  • Insights
  • Our team
  • Offering
  • What is fractional IP counsel?
  • Evolve AI
  • Technologies
  • Insights
  • Our team

Cell and gene therapy

Investors and partners will ask how your market is protected. We make sure you have a good answer.

Evolve is a specialist pharmaceutical and biotechnology IP firm. Our cell and gene therapy practice is led by Rose Hughes, formerly Director, Patents at AstraZeneca and IP lead for its biopharma cell therapy group. Rose holds a PhD in immunology and has led IP due diligence and deal negotiation on high-value cell therapy transactions. 

Explore our technology areas

Why a specialist firm Technology areas Our expertise FAQs Fractional IP Our services Insights

Why you need a cell therapy IP specialist

Cell and gene therapy IP is different. The competitive threat is a fast follower rather than a biosimilar, different kinds of IP are available, and explaining its value takes an understanding of the science, the complexities of manufacturing, regulation and commercialisation, and how a deal gets done.

We protect your market against the competition that matters

Loss of exclusivity for a cell therapy is rarely set by the expiry of a narrow product patent or the end of regulatory exclusivity. It is set by competitors, whether another product of the same modality or a different modality reaching the same indication. The durable IP position is built around the features that drive efficacy and safety. Read more: Patents versus regulatory exclusivity | Bridging the innovation and commercialisation gap

We know when to patent a process and when to keep it secret

Process patents filed early may get designed around, change over time, become prior art against your own improvements and be difficult to enforce. Early manufacturing innovation is often better held as a trade secret. We help separate company know-how, formal trade secrets and the features worth patenting. Read more: Beyond the process | T 0868/23

We know how to protect your cell therapy product with IP that will be attractive to investors and partners

If the definitions are too narrow, the clinical product can fall outside the claimed markers. If they are too broad, the claim is exposed to insufficiency, and inaccurate or outdated definitions can undermine validity and scope. Read more: Defining the undefinable | A new way to define T cells

We find IP others may miss: treatment protocol, platform and field-blocking claims

Advanced therapies open up IP opportunities that other technologies do not. Treatment protocol inventions, broader platform claims and field-blocking IP around targets, delivery and cell types can protect a market far better than a claim to one construct. Read more: T 1555/23 | The universal cell therapy revolution

We can help you explain the value of your IP because we understand where the value is

Investors and pharma partners want to know how long the market is protected and why a competitor cannot design around. Answering that means knowing which IP is actually valuable. With no biosimilar pathway, the usual formula of patent expiry or regulatory exclusivity does not work for cell therapies. We forecast the protected period by weighing in-class and out-of-class competitors, labels, manufacturing capacity and the strength of treatment and platform IP, then turn a complex, layered estate into a clear account of its value, with visual tools such as the Ammonite Chart where they help.

Read more: Patents versus regulatory exclusivity | Thinking beyond the sequence | Investors | Bridging the innovation and commercialisation gap

Advanced therapies are moving from end-of-line treatments for a few patients towards durable, scalable medicines for many. That shift will come from new targets and indications, allogeneic and in vivo products, and better delivery and manufacturing, and each step creates new IP and new competition. 

Great science deserves IP that reflects its commercial value.

Our cell and gene therapy technology areas

Each area has its own science, its own patent landscape and its own scientific, regulatory and commercial pressures.

CAR-T cell therapies
Gene therapies
In vivo CAR-T
mRNA therapeutics
Regenerative cell therapies
Lipid nanoparticles (LNPs)
Macrophages

Our expertise in cell and gene therapy IP strategy

Our team combines deep scientific expertise with in-house and private practice experience of advanced therapy IP.

Cell therapy industry expertise

Our practice is led by Rose Hughes, formerly Director, Patents at AstraZeneca and IP lead for its biopharma cell therapy group, who has led IP due diligence and deal negotiation on high-value cell therapy transactions. We have sat on the client side of the table, communicated IP risk and opportunity to company boards and senior executives, and supported successful investor interactions. We understand the complexities of manufacturing, regulation and commercialisation for advanced therapies.

Scientific expertise

Our team includes scientific experts in immunology, viral vectors, biochemistry and polymer chemistry, with doctoral research in vector design and delivery, a PhD in human macrophage biology and industry experience in antibody discovery at UCB. We draft and prosecute claims to CARs, binders, engineered cells, defined cell populations, lentiviral vectors, lipid nanoparticles and RNA cargo, and to newer modalities such as CAR-macrophages.

Read more: CAR-T cell therapies | Gene therapies | mRNA therapeutics | CAR-M cell therapy

Our AI tools: Darwin (drafting) | Gilbert (quality)

Therapeutic area specialists

We are experts in oncology, autoimmune disease and neuroscience, and understand how the IP strategy differs between them, from the competing modalities and patient populations to the dosing, conditioning and endpoints that support new clinical filings. Rose Hughes was formerly Director, Patents at AstraZeneca and IP lead for its biopharma cell therapy department, covering autoimmune CAR-T and regenerative medicine programmes, and IP lead for clinical oncology CAR-T programmes.

Read more: The first CAR-T for a solid tumour | The universal cell therapy revolution

Regenerative medicine and subject matter eligibility

Stem cell and regenerative cell therapy products often face objections that they are natural products, or that they fall within exclusions for human embryos or methods of treatment. We have experience navigating these subject matter eligibility objections in patent offices around the world, and in defining heterogeneous cell populations in claims that hold.

Read more: Regenerative cell therapies | Restem v Jadi Cell | T 1259/22

Our AI tools: Popper (prosecution)

Competitive intelligence & FTO

In vivo CAR-T, LNPs and viral vectors are crowded, fast-moving fields where new filings, clinical data and deals arrive every month. We provide our clients with competitive landscape analysis so freedom to operate, patentability and partnering decisions rest on today’s picture. Knowing the landscape if crucial for making the right filing decision. 

Read more: Overcoming FTO and patentability challenges | Navigating the complex LNP IP landscape | Albert: AI-powered competitive intelligence

Our AI tools: Albert (validity and competitive intelligence) | Ammonite Chart (portfolio visualisation)

Deals, licensing & investment

In cell and gene therapy, the IP is often what is being bought. Big pharma is acquiring technology platforms capable of generating a pipeline of products rather than single drug candidates: AbbVie’s $2.1 billion acquisition of Capstan Therapeutics, AstraZeneca’s acquisition of EsoBiotec for up to $1 billion, and Eli Lilly’s agreement to acquire Kelonia Therapeutics for up to $7 billion. Together, these three deals are worth up to ten billion dollars.

What makes a platform valuable to an acquirer is layers of protection that a competitor cannot simply design around:

  • Platform claims to the delivery system, engineering approach or cell type, ring-fenced from product claims so each can be licensed or sold on its own terms.
  • Product claims to each construct and clinical candidate.
  • Clinical claims to dosing, protocols, patient groups and indications, built from the data as it emerges.
  • Process patents, trade secrets and know-how that make the product hard to replicate.
  • Clean ownership, with chain of title from founders, universities and contractors, and in-licences that cover the field and territory needed.

We have run IP due diligence and negotiated IP terms on the in-licensing side of a $2 billion+ autoimmune cell therapy deal and a $4.5 billion antibody platform collaboration, directed the out-licensing of a whole neuroscience portfolio including gene therapy assets, and handled the IP work on a $150 million non-dilutive financing and an in vivo CAR-T licence. We help companies build that layered estate before diligence starts, forecast loss of exclusivity realistically, and explain the value of their IP to investors and pharma partners in terms they can rely on.

Read more: Due diligence | Investors | Patents versus regulatory exclusivity | The great consolidation | Navigating the complex LNP IP landscape

Our AI tools: Cassandra (due diligence) | Ammonite Chart (portfolio visualisation)

In vivo CAR-T

In vivo CAR-T combines a delivery vehicle, a targeting moiety, a cargo and a CAR, and each has its own crowded landscape. We advise on:

  • Competitive intelligence: who holds what, what is coming through clinical development, and where the white space is.
  • Patentability and freedom to operate: for the delivery technology, the targeting, the cargo and the CAR, separately and in combination.
  • Platform versus product claims: how to ring-fence platform IP from product IP, so that each can be licensed, partnered or sold on its own terms in licensing and acquisition deals.
  • Speed: how to file quickly and in the right order in a field where competitors publish and file every month.
  • Positioning: how to shape the portfolio so that it is attractive to the investors, partners and acquirers buying in vivo platforms.

Our team has handled the IP work on an in vivo CAR-T licence for a Nasdaq-listed clinical-stage biotech. Our team combines experts in immunology, viral vectors, polymer chemistry and nucleic acids. 

Read more: In vivo CAR-T | The great consolidation

Our AI tools: Albert (competitive intelligence) | Ammonite Chart (landscape visualisation)

Trade secrets & manufacturing

In cell therapy the manufacturing process and the product are different assets. Process patents can be designed around, become prior art against your own improvements and be hard to enforce, so early manufacturing innovation is often better held as a managed trade secret.

We help CDMOs, biotechs and pharma companies decide what belongs where:

  • Know-how that is valuable but cannot realistically be kept secret, managed through good records and contract terms.
  • Trade secrets for process detail that cannot be detected in the product, identified, documented, restricted and covered in employment and supplier agreements.
  • Patents for features a competitor could reverse engineer or arrive at independently, with fallback positions drafted for a process that will keep changing.

We also help companies protect their confidential information in deal negotiations, collaborations and manufacturing relationships, so that what is disclosed to a partner or CDMO is controlled, recorded and covered by the right terms.

Read more: Beyond the process | T 0868/23

Our AI tools: Franklin (publication review)

FAQs

What kinds of IP protect a cell therapy product?

Several layers, which arrive at different times:

  • Product patents for the CAR or binder, the nucleic acid, the vector, the engineered cell and the defined cell population.
  • Method of treatment and medical use patents for responding patient subpopulations and each new indication.
  • Treatment protocol patents for dosing schedules, conditioning and lymphodepletion regimens, combination therapies and the monitoring and management of side effects such as cytokine release syndrome. These can reach a whole class of products, as T 1555/23 shows.
  • Process patents for manufacturing steps and analytics that can be detected or reverse engineered.
  • Platform patents for technology that is reusable across more than one product, such as a delivery system or an engineering approach.
  • Trade secrets for manufacturing detail that cannot be seen in the product, identified, documented, restricted and covered in employment and supplier agreements.
  • Know-how, the experience of making and handling the product that is valuable but hard to keep secret, protected through good records and contract terms in collaborations, licences and CDMO agreements.

Regulatory exclusivity, patent term extensions and SPCs sit alongside these and extend the protected period. Much of the clinical and process IP is generated by the programme itself and can be claimed from data a company already holds.

Read more: T 1555/23 | Bridging the innovation and commercialisation gap | Beyond the process | Patents versus regulatory exclusivity

Do we need a specialist cell therapy patent attorney, or will a general firm do?

A general firm can file a cell therapy patent. A specialist will see which patents to file, and when. Knowing the industry is crucial. Cell and gene therapy is complex, fast-moving and different from conventional modalities such as small molecules and antibodies, so the usual approaches to protection and loss of exclusivity do not transfer.

You need someone who understands the commercial, regulatory and scientific challenges of these products and how they fit with the IP: how manufacturing and release criteria shape the claims, how regulatory interactions affect filing timing, how in-class competitors erode the market, and how deals are valued. Cell therapy IP turns on defining a highly complex product, separating process from product, capturing clinical IP from early data and forecasting loss of exclusivity against fast followers. It helps to have attorneys who understand the immunology, the vectors and the deal dynamics, and who have done the job in-house.

We are a US or non-European company. Why use a European firm?

We are a team of patent directors and attorneys who have managed global IP portfolios in-house. Patent strategy for pharma has to take account of the global strategy from day one. We can advise on multijurisdictional IP strategy and align filing footprints and priorities to the commercial plan. We draft applications for priority filings in US and Europe, can advise on navigating global patentability, grace period provisions and prior use considerations. We currently act as fractional IP counsel for US and European-based clients. 

Read more: International IP counsel | Oppositions and appeals

Can you act as our head of IP?

Yes. As fractional IP counsel, one of our patent directors acts as your head of IP for an agreed number of days a month, reporting to the board, sitting in R&D and regulatory meetings and negotiating IP terms. Rose Hughes currently acts as lead IP counsel to a Nasdaq-listed clinical-stage cell therapy company.

Read more: Fractional IP counsel

How do you patent a CAR-T construct in Europe and the US?

With a layered claim set. Product claims to the CAR, the binder and the engineered cell, supported by sequence and functional data, sit alongside method of treatment claims for the indications, dosing and patient groups, and process claims where the process can be detected.

The US and Europe then need different handling. In Juno v Kite the US Federal Circuit held a broad CAR claim invalid for lack of written description, so broad product claims to a genus of binders need substantial support. Method of treatment claims can fare better: in Teva v Eli Lilly the court upheld treatment claims to a known class of humanised antibodies, disclosed with only one humanised example. The EPO asks whether the therapeutic effect is credible across the whole claim, and post-published data can undermine a broad functional claim. The claim set has to be drafted to survive both.

Read more: Juno v Kite | Teva v Eli Lilly

How long will our cell therapy market be protected?

Usually not as long as a patent expiry date or regulatory exclusivity suggests. There is no agreed biosimilar pathway for CAR-T, so the threat is the fast follower, an in-class competitor with a different binder or another modality aimed at the same indication. Yescarta’s US regulatory exclusivity runs to 2029, yet its revenue fell 5% between 2024 and 2025, probably in part because of Breyanzi, which has an entirely different CAR sequence, and T cell engagers in the same indication.

The protected period is set by competitors. Patents on the method of treatment, dose, patient subpopulation and treatment protocol often protect the market far better than a patent on the binder sequence alone, and broad, non-sequence-limited CAR-T patents are now being asserted between competitors at the Unified Patent Court.

Read more: Patents versus regulatory exclusivity | Thinking beyond the sequence

Should we patent our manufacturing process?

Often not on its own. Process claims are designed around, become obsolete as the process changes and are hard to enforce because infringement cannot be seen in the finished product. Where the process really is the advantage, a managed trade secret is usually better. Features a competitor could arrive at independently, or that can be reverse engineered, are often still worth patenting, so most companies need a hybrid strategy.

Where you do patent, plan for change. In T 0868/23 a CAR-T manufacturing claim was tied to specific activation conditions, and the EPO’s strict approach to added matter makes it hard to amend towards the parameters a process ends up using. An early filing can also become prior art against your own improvements. Applications need fallback positions for each parameter and combination you might later need.

Read more: T 0868/23 | Beyond the process

Our CAR is novel. Do we have freedom to operate?

Not necessarily. A novel CAR can still sit inside a broader granted right, and patents on targeting molecules cover the molecule per se, so an antibody, ADC or bispecific patent on your target can block a cell therapy. With CAR-T now approved in a solid tumour, the competition for a target often comes from other modalities, and scFv binders may be reused across them. The vector, payload, process and cell source need clearing too. We can conduct initial landscape reviews, sequence and lipid structure searches and advise on patentability and infringement in this complex field. 

Read more: IP strategy for cell therapy: FAQs | The first CAR-T for a solid tumour

Fractional IP counsel for cell and gene therapy companies

Senior, in-house-calibre IP leadership on a flexible retainer, available from seed stage rather than only at the point of a transaction.

As fractional in-house IP counsel we support portfolio strategy, report IP risks and opportunities to the board, sit in the R&D and regulatory conversations where filing timing is actually decided, and negotiate IP term sheets. Rose Hughes currently acts as lead IP counsel to a Nasdaq-listed clinical-stage cell therapy company, directing its IP strategy.

We act as fractional in-house IP counsel, so this thinking is available from seed stage. Investors and acquirers ask how long the market is protected and why a competitor cannot simply design around. We help our clients answer both questions so they can be successful in diligence and partnering.

Fractional IP counsel

Client, cell therapy biotech

“Rose provides rapid, expert IP strategy advice in cell and gene therapy, combining strong sector knowledge with the ability to quickly understand complex technologies.”

Our services

Choose a service to read more.

Fractional IP counsel
Start-ups and spin-outs
Investors
Due diligence
Established pharma
Oppositions and appeals
International IP counsel

Cell therapy Evolve Insights

Gold antibody shape with one glowing turquoise arm tip on dark blue, Evolve abstract article image.
Gold antibody shape with one glowing turquoise arm tip on dark blue, Evolve abstract article image.

Is a CAR sequence patent enough to protect a CAR-T? 2seventy bio v Johnson & Johnson at the UPC

  • 8th September 2026
The loss of market share we are already seeing for on-market cell therapy products is a result of in-class competitors for the same target and indication from rival innovator companies, not copycat products with identical CAR sequences.
Row of gold panels with one turquoise panel inserted on dark blue, Evolve gene therapies image
Row of gold panels with one turquoise panel inserted on dark blue, Evolve gene therapies image

IP strategy for Cell Therapy: FAQs

  • 21st August 2026
When do we need a freedom to operate opinion for our cell therapy product? Only once the product is finalised and heading into the clinic. A full opinion on a construct, a formulation and a process that are all still moving will be out of date before it is delivered, so the right moment is…
Sphere of gold hexagon plates with glowing turquoise seams on dark blue, Evolve abstract article image.
Sphere of gold hexagon plates with glowing turquoise seams on dark blue, Evolve abstract article image.

Navigating the complex LNP IP landscape

  • 1st July 2026
It is difficult to find a field of patent law in pharma and biotech at the moment that is more complicated and fast-moving than the field of lipid nanoparticles (LNPs). IP strategy for LNPs involves sophisticated science, multiple and overlapping technology platforms, trade secret and ownership disputes and global patent cross-litigation.
Gold bar dissolving into turquoise fragments at its centre on dark blue, Evolve abstract article image
Gold bar dissolving into turquoise fragments at its centre on dark blue, Evolve abstract article image

The first CAR-T for a solid tumour has arrived: What satri-cel’s approval means for the market

  • 22nd June 2026
On 22 June 2026, China’s National Medical Products Administration (NMPA) approved satricabtagene autoleucel, or satri-cel, making it the world’s first CAR-T cell therapy cleared for a solid tumour. Developed by Shanghai-based CARsgen Therapeutics, the therapy is approved in China for patients with Claudin18.2-positive, HER2-negative advanced gastric and gastro-oesophageal junction (GEJ) cancer who have already failed…
Flight of gold steps with one turquoise glowing step on dark blue, Evolve abstract article image
Flight of gold steps with one turquoise glowing step on dark blue, Evolve abstract article image

Can you patent a stem cell product in the US? Product-by-process claims after Restem v Jadi Cell

  • 21st May 2026
Patenting stem cell therapies in the US is a difficult business, especially if your cell therapy product is defined solely by natural surface cell markers and lacks any form of genetic modification.
Swarm of gold spheres with one large turquoise sphere at the centre on dark blue, Evolve abstract article image
Swarm of gold spheres with one large turquoise sphere at the centre on dark blue, Evolve abstract article image

How should cell therapy patents define T cells? The new T cell nomenclature and what it means for IP

  • 27th March 2026
A primary objective of a pharmaceutical patent is to provide robust protection for the drug product itself. Defining a cell therapy product represents a challenge in this respect, given their inherent complexity, heterogeneity and instability.
Gold block of two interlocking pieces with a turquoise joint on dark blue, Evolve abstract article image.
Gold block of two interlocking pieces with a turquoise joint on dark blue, Evolve abstract article image.

Are cell therapy safety protocols worth patenting? Lessons from T 1555/23

  • 11th March 2026
The patent in T 1555/23 is impressively broad. The claims covered a medical use invention comprising treating the side effects of CAR-T cell therapy using the now industry-standard class of cytokine inhibitor. The claim was not limited to any particular CAR-T cell therapy, target, type of cancer or specific inhibitor.
Swarm of gold spheres with one large turquoise sphere at the centre on dark blue, Evolve abstract article image
Swarm of gold spheres with one large turquoise sphere at the centre on dark blue, Evolve abstract article image

CAR-Macrophage (CAR-M) cell therapy: Advantages, challenges, and emerging innovations

  • 20th October 2025
Are macrophages the next big thing in cell therapy?
Gold band splitting into three branches at a turquoise junction on dark blue, Evolve abstract article image
Gold band splitting into three branches at a turquoise junction on dark blue, Evolve abstract article image

Overcoming the freedom to operate and patentability challenges for cell therapies

  • 9th September 2025
How do you navigate the freedom to operate and patentability challenges in a field as complex, competitive and crowded as cell therapy?
Gold strands braiding into one cord with a turquoise join on dark blue, Evolve abstract article image
Gold strands braiding into one cord with a turquoise join on dark blue, Evolve abstract article image

Bridging the innovation and commercialisation gap: IP strategy for advanced therapies

  • 5th September 2025
Three principles of effective IP strategy for cell and gene therapies.
Gold ribbon twisting once to reveal a turquoise underside on dark blue, Evolve abstract article image
Gold ribbon twisting once to reveal a turquoise underside on dark blue, Evolve abstract article image

IP strategy for the universal cell therapy revolution

  • 27th August 2025
The cell therapy landscape is at a pivotal moment. There is considerable pressure within the industry to solve the manufacturing and logistical challenges that have defined the first generation of cell therapies.
Gold strands braiding into one cord with a turquoise join on dark blue, Evolve abstract article image
Gold strands braiding into one cord with a turquoise join on dark blue, Evolve abstract article image

The great consolidation: Big Pharma buys the advanced therapy technology, not just the drug

  • 8th August 2025
The latest cell and gene therapy industry trends reveal a shift in strategy towards platforms.
Single cut gold stone glowing turquoise at its heart on dark blue, Evolve abstract article image
Single cut gold stone glowing turquoise at its heart on dark blue, Evolve abstract article image

Do you need comparative data to patent an advanced therapy in Europe? Lessons from T 0827/23

  • 4th August 2025
Your biotech invention works, but can you prove it’s better? A recent EPO ruling on extracellular vesicles (T 0827/23) shows why the lack of comparative data can be fatal for a patent.
Stack of gold slabs with a glowing turquoise middle layer on dark blue, Evolve abstract article image.
Stack of gold slabs with a glowing turquoise middle layer on dark blue, Evolve abstract article image.

Why are cell therapy process patents fragile at the EPO? Added matter in T 0868/23

  • 8th July 2025
In cell therapy the industry mantra is that the product is the process. However, this case illustrates that the best patent protection for a cell therapy is derived from the product. 
Nested gold frames with a glowing turquoise centre on dark blue, Evolve abstract article image
Nested gold frames with a glowing turquoise centre on dark blue, Evolve abstract article image

How do you define a cell therapy product in a patent claim?

  • 13th May 2025
Understanding cell therapies for intellectual property protection is uniquely challenging because these living products are inherently complex and variable, making precise legal definitions difficult but crucial.
Gold bar dissolving into turquoise fragments at its centre on dark blue, Evolve abstract article image
Gold bar dissolving into turquoise fragments at its centre on dark blue, Evolve abstract article image

Can you patent a stem cell therapy method in Europe? Lessons from T 1259/22

  • 29th April 2025
IP strategy for cell therapy also has unique challenges. The patent at issue in T 1259/22, although relatively old (expiring August 2024 with SPCs), nonetheless highlights some of the key challenges for cell therapy IP strategy.
Stack of gold plates fanning open around a turquoise light on dark blue, Evolve abstract article image
Stack of gold plates fanning open around a turquoise light on dark blue, Evolve abstract article image

Can you claim a CAR against any target? US written description after Juno v Kite

  • 29th April 2025
The decision in Juno v Kite is not a surprise in light of the recent CAFC case law on written description for antibodies, and represents yet another nail in the coffin of functional genus claiming for biomolecules in the US.
Stack of gold slabs with a glowing turquoise middle layer on dark blue, Evolve abstract article image.
Stack of gold slabs with a glowing turquoise middle layer on dark blue, Evolve abstract article image.

Can you patent a cell therapy product, not just the process?

  • 29th April 2025
Cell therapy represents one of the most exciting fields of innovation, with the potential to provide long-term cures for previously incurable diseases. However, unlike traditional pharmaceuticals, these “living medicines” present unique IP challenges that can make or break a biotech’s future.
Flight of gold steps with one turquoise glowing step on dark blue, Evolve abstract article image
Flight of gold steps with one turquoise glowing step on dark blue, Evolve abstract article image

How do you calculate loss of exclusivity for a cell therapy? Patents versus regulatory exclusivity

  • 29th April 2025
Conventional approaches to LoE fail to capture the complex reality of cell therapy products. IP strategy for cell therapy needs to be adapted to take account of these realities.
Grid of gold cubes with one turquoise cube lifted on dark blue, Evolve AI drug discovery image
Grid of gold cubes with one turquoise cube lifted on dark blue, Evolve AI drug discovery image

Too broad, too early? AI platform for cell analysis found to lack technical character and sufficiency (T 0660/22, Cell analysis/NIKON)

  • 29th April 2025
This decision highlights some of the challenges associated with trying to broadly protect software-based platform technology for biological research.
View more Insights

Contact us

Tell us where your programme is and what is coming up, whether that is a first filing, a landscape, a financing, a partnering process or a deal.

We are happy to have an informal conversation about your programme, with no obligation. You can read more about Rose Hughes, who leads our cell and gene therapy practice, and the rest of our team. We also write a regular newsletter on pharma and biotech IP.

Contact us
Subscribe to the newsletter

evolve® is a trading entity of Evolve Intellectual Property Limited. Evolve Intellectual Property Limited is regulated by the Intellectual Property Regulation Board (IPReg). Details of the UK professional rules can be found on the IPReg website

registered address: 49 Greek Street, London, England, W1D 4EG

website out of house

© 2026 All Rights Reserved

Keep in touch

  • Subscribe
  • Contact us
  • Cookie Notice
  • Complaints Procedure
  • Privacy notice
  • Subscribe
  • Contact us
  • Cookie Notice
  • Complaints Procedure
  • Privacy notice